Immunohistochemical Expression of Basic Fibroblast Growth Factor and Fibroblast Growth Factor Receptors 1 and 2 in the Pathogenesis of Lung Cancer

Carmen Behrens,1 Heather Y. Lin,2 J. Jack Lee,2 Maria Gabriela Raso,3 Waun Ki Hong,1 Ignacio I. Wistuba,1,3 and Reuben Lotan1

Abstract

**Purpose:** To identify the patterns of protein expression of basic fibroblast growth factor (bFGF) and FGF receptors 1 and 2 in non-small cell lung carcinoma (NSCLC) and their role in the early pathogenesis of squamous cell carcinoma (SCC) of the lung.

**Experimental Design:** Archived tissue from NSCLC (adenocarcinoma and SCC; n = 321) and adjacent bronchial epithelial specimens (n = 426) were analyzed for the immunohistochemical expression of bFGF, FGFR1, and FGFR2, and the findings were correlated with clinicopathologic features of the patients.

**Results:** High expression of bFGF, FGFR1, and FGFR2 was shown in most NSCLC tumors. The pattern of expression for all markers varied according to tumor histologic type and cellular localization. Cytoplasmic expression scores were significantly higher in tumors than in normal epithelia. Nuclear bFGF (P = 0.03) and FGFR1 (P = 0.02) levels were significantly higher in women than in men. Although cytoplasmic FGFR1 expression was significantly higher (P = 0.002) in ever smokers than in never smokers, nuclear FGFR1 (P = 0.0001) and FGFR2 (P = 0.003) expression was significantly higher in never smokers. Different prognostic patterns for the expression of these markers were detected for both NSCLC histologic types. Dysplastic changes showed significantly higher expression of all markers compared with squamous metaplasia.

**Conclusions:** bFGF, FGFR1, and FGFR2 are frequently overexpressed in SCC and adenocarcinoma of the lung. bFGF signaling pathway activation may be an early phenomenon in the pathogenesis of SCC and thus an attractive novel target for lung cancer chemopreventive and therapeutic strategies.
Expression of bFGF and Its Receptors in Lung Cancer

Translational Relevance
A better understanding of the signaling pathways that lead to tumor growth and angiogenesis may help in the development of new and more effective strategies for targeted chemoprevention and treatment of lung cancer. Our findings of frequent overexpression of bFGF, FGFR1, and FGFR2 in NSCLC, and in the early pathogenesis of squamous cell carcinomas, suggest that the activation of the bFGF pathway, which has been proposed to facilitate the development of resistance to antiangiogenic therapy targeting the vascular endothelial growth factor pathway, is an attractive novel target for lung cancer therapeutic and chemopreventive strategies.

Materials and Methods

Case selection and TMA construction. For this study, which was approved by our institutional review board, we obtained archived formalin-fixed, paraffin-embedded material from surgically resected lung cancer specimens containing tumor and adjacent lung tissues from the Lung Cancer Specialized Program of Research Excellence tissue bank at The University of Texas M. D. Anderson Cancer Center. Tissue specimens collected between 1997 and 2003 from 321 lung cancer tumors (196 adenocarcinomas and 125 SCCs) were classified by using the 2004 WHO classification system (3) and selected specimens were used for construction of TMAs. In addition, detailed histopathologic semiquantitative analysis of lung adenocarcinoma subtypes (acinar, papillary, solid with mucin, and bronchioloalveolar) using the WHO classification (3) was done in 192 lung adenocarcinomas. After histologic examination, the NSCLC TMAs were constructed by obtaining three 1-mm-diameter cores from each tumor.

To assess the immunohistochemical expression of bFGF, FGFR1, and FGFR2 in the early pathogenesis of NSCLC, we studied formalin-fixed, paraffin-embedded material from 426 specimens of bronchial epithelial foci and constructed tissue microarray (TMA) specimens. We then correlated our findings with clinicopathologic features of patients with lung cancer.

Table 1. Summary of the clinicopathologic features of lung cancer cases studied

<table>
<thead>
<tr>
<th>Feature</th>
<th>SCC (n = 125)</th>
<th>Adenocarcina (n = 196)</th>
<th>Total (N = 321)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (range), y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>79</td>
<td>74</td>
<td>153</td>
</tr>
<tr>
<td>Female</td>
<td>46</td>
<td>122</td>
<td>168</td>
</tr>
<tr>
<td>Smoking status †</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>6</td>
<td>50</td>
<td>56</td>
</tr>
<tr>
<td>Ever</td>
<td>118</td>
<td>146</td>
<td>264</td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>68</td>
<td>130</td>
<td>198</td>
</tr>
<tr>
<td>II</td>
<td>39</td>
<td>25</td>
<td>64</td>
</tr>
<tr>
<td>III</td>
<td>17</td>
<td>34</td>
<td>51</td>
</tr>
<tr>
<td>IV</td>
<td>1</td>
<td>7</td>
<td>8</td>
</tr>
</tbody>
</table>

*Values are number of cases unless otherwise indicated.
† Smoking status was not available in one patient with SCC.
stage were assessed using appropriate methods including χ² test or Fisher’s exact test for categorical variables and Wilcoxon’s rank-sum test or Kruskal-Wallis test for continuous variables. Linear mixed-effects model was applied to compare the marker expression level among various histologic progression stage including normal, hyperplasia, metaplasia, dysplasia, and cancer.

We performed overall survival (OS) and recurrence-free survival (RFS) analyses for the expression of bFGF, FGFR1, and FGFR2 by using specimens from 321 NSCLC patients with a median follow-up of 3.78 years. Survival curves were estimated using the Kaplan-Meier method. OS was defined as the time from surgery to death or to the end of the study and RFS as the time from surgery to recurrence or to the end of the study. The effect of the marker expression on patients’ OS and RFS was tested for both histologic types separately and adjusted for age, sex, smoking status, and pathologic TNM stage. The binary cutoff points of biomarkers were identified using the Classification and Regression Tree algorithm, in which a cutoff point is determined for each predictor variable such that the two resulting subgroups are the most different in OS. The same cutoffs were used in the RFS analysis.

Univariate and multivariate Cox proportional hazards models were used to assess the effect of covariates on OS and RFS. Two-sided P values < 0.05 were considered statistically significant. Any significant findings can serve as hypothesis generation and require further confirmation in future studies. All analyses were conducted in SAS 9.1 (SAS Institute) and S-PLUS (Insightful Corp.).

Results

Patients’ characteristics. We studied 321 surgically resected lung cancers representing the two major NSCLC histologies using archival tissue specimens. Detailed clinical and pathologic information was available in most cases (Table 1) and included patients’ demographic data, smoking history [never smokers or ever smokers (patients who had smoked at least 100 cigarettes in their lifetime)], pathologic TNM staging (20), OS time, and RFS time.

Immunohistochemical expression of bFGF and receptors in NSCLC compared with that in normal epithelium. bFGF, FGFR1, and FGFR2 were detected in the cytoplasm and nuclei of bronchial epithelium and tumor cells (Fig. 1). Overall, NSCLC tumor cells showed higher levels of bFGF, FGFR1, and FGFR2 protein expression than histologically normal bronchial epithelium did. No significant difference in the expression of these three markers was detected in normal epithelium obtained from patients with adenocarcinoma or SCC. Specimens from both histologic types of NSCLC, however, had significantly higher cytoplasmic expression scores for all three markers than did the histologically normal specimens of bronchial epithelium obtained from patients with lung cancer (Figs. 1 and 2). Significant higher FGFR1 and FGFR2 (but not bFGF) nuclear expression scores were also found in tumor than in normal epithelium for patients with adenocarcinoma. On the other hand, significantly higher bFGF (but not FGFRs) nuclear expression score was found in tumor than in normal epithelium in patients with squamous carcinoma (Fig. 2).

Markers of immunohistochemical expression in the sequential pathogenesis of SCC. We investigated the expression of bFGF, FGFR1, and FGFR2 in 426 epithelial specimens containing histologically normal, hyperplastic, squamous metaplastic, or squamous dysplastic bronchial epithelium adjacent to NSCLC obtained from 130 patients. Similar levels of cytoplasmic and nuclear expression were detected in normal and hyperplastic epithelia for all three markers. For cytoplasmic FGFR1 and FGFR2 localizations, squamous metaplastic epithelia showed...
significantly lower levels of the markers than did normal (FGFR1, \( P = 0.022 \); FGFR2, \( P = 0.022 \)) and hyperplastic (FGFR1, \( P = 0.047 \); FGFR2, \( P = 0.049 \)) epithelia. For nuclear localization, no significant differences in the scores of any markers were detected between normal, basal cell hyperplastic, and squamous metaplastic epithelia. Of interest, squamous dysplastic lesions showed significantly higher levels of expression than did squamous metaplastic lesions for all three markers (Fig. 3). The monotone increase pattern in the expression of these markers from squamous dysplasia to invasive SCC is consistent with the progression model of this tumor type.

**Correlation between markers of immunohistochemical expression in NSCLC and clinicopathologic features and disease outcomes.** We correlated bFGF and FGFR scores and levels of expression with tumor histologic characteristics, age, sex, smoking history, and TNM pathologic stage. The expression of these markers at the cytoplasmic level was similar in both NSCLC histologic types, except for FGFR2, which was significantly higher (\( P = 0.006 \)) in SCC (Fig. 2). At the nuclear level, SCC showed significantly higher (\( P = 0.016 \)) expression of bFGF than did adenocarcinoma, whereas the latter showed significantly higher expression of both receptors (FGFR1, \( P < 0.0001 \); FGFR2, \( P = 0.0007 \); Fig. 2).

One striking association observed was the correlation between the immunohistochemical expression of bFGF and the receptors with sex and smoking history in patients with adenocarcinoma (Table 2). Expression of nuclear bFGF and nuclear FGFR1 were significantly higher (\( P = 0.03 \) and \( P = 0.02 \), respectively) in women than in men. Although cytoplasmic FGFR1 expression was significantly higher (\( P = 0.002 \)) in ever smokers than in never smokers, expression of nuclear FGFR1 (\( P = 0.0001 \)) and nuclear FGFR2 (\( P = 0.003 \)) was significantly higher in never smokers than in ever smokers. No significant associations between all three markers and gender or smoking status were found in patients with squamous carcinoma. For both NSCLC types, no correlation was detected between marker expression and age or TNM pathologic stage. In lung adenocarcinoma, FGFR1 nuclear expression positively and significantly (Spearman’s correlation coefficient \( r = 0.29 \); Fig. 2.)
correlated with the presence of bronchioloalveolar subtype. Of interest, this correlation was independent of gender and remained significant (P < 0.003) after adjusting by smoking history in multivariate analysis (data not shown).

We analyzed the prognostic effects of the markers on disease outcomes using both a continuous score and a dichotomized score of the marker expressions using the cutoffs identified by Classification and Regression Tree algorithm. In patients with adenocarcinoma, both scores of cytoplasmic FGFR1 show a trend, although nonsignificant, effect on OS (P = 0.070 and P = 0.068, respectively, for the continuous and binary score, >195) and RFS (P = 0.087 and P = 0.12, respectively, for the continuous and binary measure) in the univariate setting. The Kaplan-Meier curves for the binary score shown in Fig. 4A indicate that high cytoplasmic FGFR1 was associated with a worse OS and a worse RFS. After adjusting for age, gender, smoking history, and pathologic stage, the effects of the cytoplasmic overexpression of FGFR1 on OS and on RFS remained marginally significant. Patients with high cytoplasmic FGFR1 had a worse OS [P = 0.07; hazard ratio (HR), 1.51; 95% confidence interval (95% CI), 0.97-2.33] and a worse RFS (HR, 1.63; 95% CI, 1.00-2.67). Of interest in these patients, when treating as a continuous variable, each one-unit increase in the FGFR1 cytoplasmic score conferred a nonsignificant trend to a better OS (P = 0.071; HR, 1.01; 95% CI, 1.00-1.02) and a significantly worse RFS (P = 0.02; HR, 1.01; 95% CI, 1.00-1.02).

In patients with SCCs, we detected a more complex pattern of prognostic association. In the univariate analyses, nuclear FGFR1 (score > 17.5) and nuclear FGFR2 (score > 55) showed close to significant or significant effects on OS (P = 0.061 and 0.031 for nuclear FGFR1 and FGFR2, respectively). Nuclear FGFR1 and FGFR2 had a significant effect on RFS (P = 0.027 and 0.021, respectively). As the Kaplan-Meier curves for the binary score in Fig. 4B show, high nuclear expression of FGFR1 was associated with a worse OS and a worse RFS. When age, gender, smoking history, and pathologic stage are compared, the nuclear overexpression of FGFR1 (score > 17.5) and FGFR2 (score > 55) significantly correlated with worse outcome in RFS and OS, respectively. The nuclear overexpression of FGFR1 conferred to patients a worse RFS (P = 0.04; HR, 1.97; 95% CI, 1.04-3.72), and the nuclear overexpression of FGFR2 correlated with worse OS (P = 0.02; HR, 2.54; 95% CI, 1.18-5.47) and RFS (P = 0.02; HR, 2.84; 95% CI, 1.18-6.86). In contrast, the cytoplasmic overexpression of bFGF (score > 175) and FGFR2 (score > 155) significantly correlated with better OS (bFGF: P = 0.02; HR, 0.55; 95% CI, 0.33-0.92 and FGFR2: P = 0.008; HR, 0.51; 95% CI, 0.31-0.83). When they are analyzed as a continuous variable, they also show trend, although nonsignificant, effects on OS and RFS. Again, high cytoplasmic bFGF is associated with a better OS (P = 0.068; HR, 0.99; 95% CI, 0.99-1.00 per unit increment). High cytoplasmic FGFR2 is associated with a better OS (P = 0.086; HR, 0.99; 95% CI, 0.99-1.00 per unit increment).

Correlations of markers’ expression. In tumor specimens, we analyzed the correlation between the expression of all markers at cytoplasmic and nuclear localizations. Comparing all three markers, we detected a complex pattern of correlations of immunohistochemical expression in NSCLC that differed between the adenocarcinoma and SCC histologic types. A positive significant correlation between the cytoplasmic and nuclear overexpression of bFGF was detected in adenocarcinoma and of FGFR2 in both adenocarcinoma and SCC. In adenocarcinoma specimens, the correlation between bFGF and FGFR1 and between FGFR1 and FGFR2 was observed at cytoplasmic and nuclear localizations, whereas these correlations were found only at cytoplasmic localizations in specimens of SCC.

Discussion

As with some other angiogenesis pathways, the bFGF pathway has been shown previously to be activated in lung cancer (11–18). Although several reports showed high levels of
expression of bFGF and FGFR1 in NSCLC, the precise role of these signaling molecules in the pathogenesis and progression of this tumor is still unclear (12–18). Eight studies that conducted immunohistochemical expression analyses of NSCLCs (including adenocarcinomas and SCCs) described frequent bFGF expression in lung tumors, ranging from 49% to 77% of lung tumors (12–17, 21, 22). In four studies about FGFR1 immunohistochemical expression in NSCLC tissue specimens, these frequencies ranged from 50% to 81% (12–15). For FGFR2, only one immunohistochemical study was done involving 61 NSCLC specimens, 50% of which showed receptor expression (21). All of these studies used different arbitrary cutoffs to assess positive immunohistochemical expression; thus, the data are difficult to interpret.

In this study, we described high levels of immunohistochemical expression of bFGF, FGFR1, and FGFR2 in a large series of NSCLC specimens, including the two most frequent histologic types, SCC and adenocarcinoma, similarly to previous studies (12–17, 21, 22). To our knowledge, this is the first comprehensive analysis of bFGF, FGFR1, and FGFR2 in the same set of NSCLC specimens. Overall, we found higher levels of bFGF and FGFRs expression in tumor cells than in adjacent normal bronchial epithelia at cytoplasmatic localization in both SCC and adenocarcinoma. These findings are consistent with the postulated mitogenic and angiogenic effects of the bFGF signaling pathway activation in human tumors, including NSCLC (8).

Lung cancers are believed to develop through a series of progressive pathologic changes (preneoplastic or precursor lesions) in the respiratory mucosa that result in an accumulation of genetic abnormalities (23). These abnormalities are frequently extensive and multifocal throughout the respiratory epithelium, indicating a field effect or field cancerization phenomenon (23). Although sequential preneoplastic changes have been defined for centrally arising squamous carcinomas, they have been poorly documented for lung adenocarcinomas (4). Mucosal changes in the large airways that may precede invasive SCC include squamous dysplasia and carcinoma in situ in the central bronchial airway (24, 25). In lung cancer pathogenesis, the genetic changes commence in histologically normal epithelium and are present in a similar frequency in mildly abnormal epithelium, including basal cell hyperplasia and squamous metaplasia (23). In our study, we describe, to our knowledge for the first time, a widespread expression of bFGF, FGFR1, and FGFR2 adjacent to histologically normal, mildly abnormal, and preneoplastic bronchial respiratory epithelium in NSCLC specimens. Our findings of a significant increase in the immunohistochemical expression of bFGF and FGFR proteins at cytoplasmatic (bFGF, FGFR1, and FGFR2) and nuclear (FGFR2) localizations in respiratory epithelium with low-grade (cytoplasmatic bFGF) and high-grade (cytoplasmatic bFGF and FGFRs and nuclear FGFR2) squamous dysplastic, compared with metaplastic, bronchial epithelia, suggest that the activation of the bFGF pathway is an early event in the pathogenesis of SCC of the lung and could play a role in the angiogenic switch characteristic of tumor promotion.

Whereas most of the previous studies reported either cytoplasmatic protein expression only (12, 13, 16) or did not indicate immunostaining cell localization (14, 15, 17, 22), we described the expression of bFGF, FGFR1, and FGFR2 at both

### Table 2. bFGF, FGFR1, and FGFR2 immunohistochemical expression in NSCLC types by histology, sex, and smoking status

<table>
<thead>
<tr>
<th>No.</th>
<th>Immunohistochemical markers, mean (SD)</th>
<th>bFGF</th>
<th>FGFR1</th>
<th>FGFR2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cytoplasmic expression score*</td>
<td>Nuclear expression score †</td>
<td>Cytoplasmic expression score*</td>
<td>Nuclear expression score †</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>74</td>
<td>169.6 (47.6)</td>
<td>8.1 (9.4)</td>
<td>196.1 (27.7)</td>
</tr>
<tr>
<td>Female</td>
<td>122</td>
<td>166.1 (46.3)</td>
<td>11.9 (12.7)</td>
<td>194.6 (28.6)</td>
</tr>
<tr>
<td>P</td>
<td>0.62</td>
<td>0.03</td>
<td>0.73</td>
<td>0.02</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>50</td>
<td>162.5 (45.0)</td>
<td>11.6 (9.6)</td>
<td>184.7 (24.2)</td>
</tr>
<tr>
<td>Ever</td>
<td>146</td>
<td>169.1 (47.3)</td>
<td>10.1 (12.3)</td>
<td>198.8 (28.6)</td>
</tr>
<tr>
<td>P</td>
<td>0.40</td>
<td>0.44</td>
<td>0.002</td>
<td>0.0001</td>
</tr>
<tr>
<td>SCC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>79</td>
<td>174.5 (33.1)</td>
<td>12.9 (13.2)</td>
<td>193.3 (24.9)</td>
</tr>
<tr>
<td>Female</td>
<td>46</td>
<td>164.3 (37.0)</td>
<td>15.1 (12.8)</td>
<td>189.1 (26.5)</td>
</tr>
<tr>
<td>P</td>
<td>0.12</td>
<td>0.36</td>
<td>0.36</td>
<td>0.80</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>6</td>
<td>176.7 (46.3)</td>
<td>5.8 (13.3)</td>
<td>185.0 (15.2)</td>
</tr>
<tr>
<td>Ever</td>
<td>118</td>
<td>170.2 (35.1)</td>
<td>14.1 (13.2)</td>
<td>192.3 (25.5)</td>
</tr>
<tr>
<td>P</td>
<td>0.66</td>
<td>0.13</td>
<td>0.48</td>
<td>0.86</td>
</tr>
</tbody>
</table>

*Cytoplasmic immunostaining expression was quantified using a four-value intensity score (0, 1+, 2+, and 3+) and the percentage (0-100% of the extent of reactivity. The cytoplasmic expression score was obtained by multiplying both intensity and reactivity extension values (range, 0-300).

† Nuclear immunostaining expression was quantified using a range of 0 to 100 according to the percentage of positive nuclei.
cytoplasmic and nuclear localizations in our NSCLC specimens. These findings are consistent with previous in vitro studies showing that bFGF and FGFR1 translocate to the cell nucleus (26). In addition, the nuclear localization of bFGF in cells has been known for many years (27, 28), and there is some evidence that this translocation is required for the induction of cell proliferation (29). More recently, it has been shown that on cell stimulation with bFGF, FGFR1, a plasma membrane-associated protein, is undergoing endocytosis to the cytosol and translocates to the cell nucleus along with its ligand bFGF (26). Within the nucleus, FGFR1 serves as a general transcriptional regulator that activates structurally distinct genes located on different chromosomes and stimulates multigene programs for cell growth and differentiation (26).

In the correlation analysis of the immunohistochemical expression of bFGF and its receptors and patients' clinicopathologic characteristics, we found, somewhat surprisingly, a significantly higher level of nuclear bFGF and FGFR1 expression in tumor specimens obtained from female patients than in specimens from male patients with adenocarcinoma. These findings link the phenomenon of angiogenesis with sex-related oncogenic mechanisms, including sex steroid hormones. In women, the effects of estrogen and progesterone in angiogenesis pathways such as those associated with vascular endothelial growth factor have been established in normal endometrial and breast tissues (30–33) and are being investigated in the corresponding tumors (34, 35). In the bFGF pathway, much less is known about whether sex steroids are involved with the regulation of normal and malignant tissues. In the normal endometrium, bFGF mRNA has shown a cyclic variation, suggesting that at least mRNA levels may be regulated by sex steroids (36). In breast cancer, bFGF levels seem to be up-regulated compared with normal adjacent tissue and associated with a high expression of the estrogen receptor, suggesting a correlation between them (35). The role of hormones, particularly estrogen, as a risk factor for the development of lung cancer among women is an area of vigorous investigation (37), and in NSCLC, there is evidence of cross-talk between the estrogen receptor and other growth factor signaling pathways, including the epidermal growth factor receptor (38).

In addition, in adenocarcinoma specimens, we detected differences in the expression of the three markers and patients' smoking status, with cytoplasmic FGFR1 expression being significantly higher in smokers and nuclear FGFR1 and FGFR2 significantly higher in never smokers. To our knowledge, these associations have not been reported.

Fig. 4. Kaplan-Meier curves illustrating FGFR1 cytoplasmic protein expression for adenocarcinoma (A) and FGFR1 nuclear expression for SCC (B) patients.
previousl y. These differences highlight the potential differential roles of these proteins in the pathogenesis of both smoking and non-smoking-related lung cancers. There is some evidence that links the bFGF pathway with smoking in lung diseases. It has been suggested that the bFGF pathway plays a role in regulating airway wall remodeling, especially in individuals with smoking-induced chronic obstructive peripheral disease, which is related to inflammation of the small airway (39). Of interest, Kranenburg et al. (40) conducted an immunohistochemical analysis of bronchial specimens obtained from patients with chronic obstructive peripheral disease and showed that FGFR1 immunolocalized in the cytoplasm of bronchial epithelial cells and in other cell components of the bronchial wall. We hypothesize that the inflammatory phenomenon occurring in smoking-damaged airway may be associated with the predominantly cytoplasmic localization of these receptors. Our finding of the differential expression of cytoplasmic FGFR2 and of both receptors at the nuclear level with smoking status in tumor specimens needs further study in epithelial lesions.

The prognostic effect of the expression of bFGF, FGFR1, and FGFR2 proteins in lung cancer has been studied previously in a limited number of tumor cases (14, 16, 17, 21). In NSCLC, high levels of bFGF expression, determined by ELISA in tissue extracts (n = 71; ref. 17) and by immunohistochemical expression in the cytoplasm of tumor cells (n = 119; ref. 16), correlated with worse OS. Similarly, high levels of FGFR1 and FGFR2 expression correlated with shorter OS in patients with NSCLC (n = 206; ref. 14) and lung adenocarcinomas (n = 30; ref. 21). When we investigated the correlation of the expression of these markers with OS and RFS, our findings suggested that the overexpression of FGFR1 in the cytoplasm of tumor cells correlated with worse OS only in patients with adenocarcinoma, similar to findings reported by Yamayoshi et al. (21). In contrast, for SCC, we found that the nuclear overexpression of FGFR1 and FGFR2 correlated significantly with worse outcome in both OS and RFS. Somewhat surprisingly, the cytoplasmic overexpression of bFGF and FGFR2 in squamous tumor cells correlated with better OS. Although it seems paradoxical that a tumor that expresses high levels of bFGF and FGR exhibits a better prognosis than a tumor that expresses low levels, we hypothesize that high levels of cytoplasmic expression may prevent nuclear localization of the proteins. Our data confirmed the notion that adenocarcinoma and SCC are not a homogeneous group of tumors and that they should always be examined separately for molecular targets and outcome.

We identified multiple correlations between the immunohistochemical expression of bFGF, FGFR1, and FGFR2 and their cytoplasmic and nuclear tumor cell localizations. All correlations but one were positive. Of interest, we detected a correlation between bFGF and FGFR1 expression in both NSCLC histologic types at the cytoplasmic level. These findings suggest that the cytoplasmic overexpression of the ligand bFGF in tumor cells may influence the expression and cell internalization of FGFR1. In lung adenocarcinomas, this association was also found at the nuclear level, emphasizing the role of bFGF in FGFR1 translocation to the cell nucleus (26). A similar pattern of association was detected between both FGFRs, a phenomenon that could be associated with preferential receptors dimerization and subsequent cytoplasmic internalization and nuclear translocation.

In summary, our findings indicate that bFGF, FGFR1, and FGFR2 are frequently overexpressed in NSCLC, although different patterns of expression are detected in its two major types. Our findings further suggest that bFGF signaling pathway activation is an early phenomenon in the pathogenesis of SCC of the lung. In addition, the frequent and early overexpression of bFGF and FGFR markers in patients with NSCLC suggests that the activation of the bFGF pathway, which has been proposed to facilitate the development of resistance to antiangiogenic therapy targeting the vascular endothelial growth factor pathway (41), is an attractive novel target for lung cancer therapeutic and chemopreventive strategies.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

References


Immunohistochemical Expression of Basic Fibroblast Growth Factor and Fibroblast Growth Factor Receptors 1 and 2 in the Pathogenesis of Lung Cancer


*Clin Cancer Res* 2008;14:6014-6022.

Updated version  Access the most recent version of this article at:  http://clincancerres.aacrjournals.org/content/14/19/6014

Cited articles  This article cites 40 articles, 6 of which you can access for free at:  http://clincancerres.aacrjournals.org/content/14/19/6014.full#ref-list-1

Citing articles  This article has been cited by 14 HighWire-hosted articles. Access the articles at:  http://clincancerres.aacrjournals.org/content/14/19/6014.full#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.